Australian clinical-stage company Immutep has announced positive data from the INSIGHT-003 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer. …
Australian company says 'Efti' INSIGHT-003 lung cancer trial reveals positive survival data
November 14, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
A response based on short-term considerations only undermines long-term objectives
November 15, 2024 - - Latest News -
Amplia enters into preclinical collaboration with Korean drug screening company
November 14, 2024 - - Australian Biotech -
Botanix expands US payer coverage for Sofdra with Ascent Health agreement
November 14, 2024 - - Australian Biotech -
Australian company says 'Efti' INSIGHT-003 lung cancer trial reveals positive survival data
November 14, 2024 - - Latest News -
'A procurement mindset must not impede equitable access to medicines that offer significant benefits'
November 14, 2024 - - Latest News -
MA proposes CEO for HTA Review implementation group and wants 'continuity'
November 14, 2024 - - Latest News -
Any approach to government relations based on the Montessori method is doomed to fail
November 14, 2024 - - Latest News